dramophilos envía lo siguiente, y se pregunta: "¿Qué fue primero? ¿La pandemia o el negocio multimillonario para producir la vacuna?" ¿Cómo la ven?
Sanofi Aventis Invests 100 Million Euros In New Facility In Mexico To Produce Seasonaland Pandemic Influenza Vaccine
Main Category: Pharma Industry / Biotech Industry
Also Included In: Immune System / Vaccines
Article Date: 19 Mar 2009
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY), announced the signing of an agreement with the Mexican authorities to build a 100 million euro facility to manufacture influenza vaccine in Mexico.
The announcement was made during a ceremony attended by Felipe Calderon, President of Mexico, and Nicolas Sarkozy, President of France, who was in Mexico City for a State visit.
This facility will be built and operated by sanofi pasteur, the vaccines division of sanofi-aventis Group, which was represented at the ceremony by Chris Viehbacher, Chief Executive Officer of sanofiaventis. "By building this new facility, sanofi-aventis is proud to contribute to the strengthening of Mexico's health infrastructure and is eager to support Mexico's exemplary commitment to public health through influenza immunization and pandemic readiness", said Chris Viehbacher. "This investment illustrates sanofi-aventis' local approach to global health. This facility will benefit public health in Mexico and the Latin American region, in the context of influenza pandemic preparedness".
The agreement was signed by Birmex' (Laboratorio de Biológicos y Reactivos de México) and sanofi-aventis' representatives in the presence of Dr. José Ángel Córdova Villalobos, Minister of Health of Mexico.
Under the terms of the agreement, sanofi pasteur will manufacture influenza vaccine in collaboration with Birmex, a Mexican federal vaccine manufacturer. Birmex will perform certain stages of manufacturing and will be responsible for distributing influenza vaccines to the public in Mexico. Sanofi pasteur is planning to start construction of the new vaccine manufacturing facility within a few weeks. Upon completion within four years, the facility will have a yearly capacity of up to 25 million doses of seasonal influenza vaccine.